Pomalidomide (CC-4047)

For research use only. Not for use in humans.

製品コードS1567

Pomalidomide (CC-4047)化学構造

CAS No. 19171-19-8

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 17100
JPY 13600
JPY 63400
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(74)

製品安全説明書

E3 ligase Ligand阻害剤の選択性比較

生物活性

製品説明 Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
特性 A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
ターゲット
CRBN [5]
()
TNF-α [1]
(PBMCs)
13 nM
体外試験

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NXjjSplyS3m2b4TvfIlkcXS7IFHzd4F6 NUfyWWRjOTBizszN NHu4Z4czPCCq M3XWdpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= NV3ZbIZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN|gzPzNpPkK2N|M5Ojd|PD;hQi=>
J-CD38 Mo\6R5l1d3SxeHnjbZR6KEG|c3H5 MljNNVAh|ryP NFmxelQzPCCq NH3RdGFxd3SnboTsfUBifWevZX70d{BlcXKnY4SgZY5lKGmwZHny[YN1KE2PIHPlcIwhc2mubHnu[{BjgSCVQWK= NXi1NHBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN|gzPzNpPkK2N|M5Ojd|PD;hQi=>
R-CD38 MVLDfZRwfG:6aXPpeJkhSXO|YYm= NXPPZ2tiOTBizszN MWCyOEBp MWPwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? NVP1ZWk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN|gzPzNpPkK2N|M5Ojd|PD;hQi=>
BC-3 NGO2UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXezPU0yOjVyIH7N MmroOUBl MV7EUXNQyqB? MkX4TWM2OD1zMEegcm0tKGmwaHnibZR{KGOnbHygTWM2OD1zMEegcm0tKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHHUZlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
BCBL-1 NYfPb|dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2zPU0yOjVyIH7N MmrHOUBl NUfkSW1ETE2VT9Mg NF:3bI1KSzVyPUe0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVnNTFZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
JSC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOzPU0yOjVyIH7N NEX2cFQ2KGR? MXPEUXNQyqB? NWP5eHE3UUN3ME2zOEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NID3doc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
VG-1 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK3N2RFOzlvMUK1NEBvVQ>? NYLQb5FiPSCm NFL6fo5FVVORwrC= NUntdHFtUUN3ME2xNFEhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M{XnXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-1 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn5Z4M{QS1zMkWwJI5O NEDoelY2KGR? M4jTUmROW00EoB?= MYnJR|UxRTN{IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXzVfYFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
UMPEL-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTRN|kuOTJ3MDDuUS=> NHzGco02KGR? NXe1bIt{TE2VT9Mg M1LqbmlEPTB;MUGxJI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 M17xR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BC-1 NVjHW|RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pOVM6NTF{NUCgcm0> MW[1JIQ> NFjJWVdFVVORwrC= NFuy[|lKSzVyPUe0OEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BCP-1 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLN|kuOTJ3MDDuUS=> NIj1elU2KGR? NFvzZ2ZFVVORwrC= NF2xcYtKSzVyPUO5OkBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NF;DVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
APK-1 NWn0VVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG1SVRlOzlvMUK1NEBvVQ>? Mne0OUBl NFrmfoZFVVORwrC= NXG4eIJHUUN3ME2yNlYhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M{D5ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
RPMI8226  NGrSZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0UoFHOC5yMT21NEDPxE1? MYK0PEBp M3nYVWROW00EoB?= M2[5eGlEPTB;ODFOwG0> NGLucJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
OPM2  NY\NZ|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7PWJpZOC5yMT21NEDPxE1? MkXEOFghcA>? M1vFXmROW00EoB?= MkfSTWM2OD1zMDFOwG0> NWPx[XRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
RPMI8226  NEXLbFBHfW6ldHnvckBCe3OjeR?= NUDk[GxvOTBizszN M3\4OlQ5KGh? MmLpSG1UV8Li MoDnd5Rz\W6pdHjlcpMh[3m2b4DsZZNucWNvboXjcIVieiC|aIX0eIxqdmdib3[gcXRQWiCjbnSgdE1uXE:UIIDyc5RmcW5? NVLZVINnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
OPM2  MkHCSpVv[3Srb36gRZN{[Xl? Moj3NVAh|ryP NYew[XVSPDhiaB?= NVrrNpJoTE2VT9Mg NEn2N3N{fHKnbnf0bIVveyCleYTvdIxie22rYz3ueYNt\WG{IIPoeZR1dGmwZzDv[kBuXE:UIHHu[EBxNW2WT2KgdJJwfGWrbh?= MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUe4O|IoRjJ4MEm3PFczRC:jPh?=
RPMI8226 MnnjSpVv[3Srb36gRZN{[Xl? M3zpRVAvOS1zMDFOwG0> NGTjcWk1KGh? NYfE[nQxTE2VT9Mg NXHyV|FocW6lcnXhd4V{KF[HR1[gcXJPSSCneIDy[ZN{cW:w MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3M{m5NEc,OjVyNUO5PVA9N2F-
SH-SY5Y  NFSwOYZCeG:ydH;zbZMhSXO|YYm= MXGyOeKh|rypL33M NWHDTnJ5OcLiaB?= MlP4Z4F2e2W|IIP0ZZRqe3SrY3HscJkhe2mpbnnmbYNidnRicnXkeYN1cW:wIHnuJIJwfGhiQ2DGMUBidmRiQ2DGL2NONWmwZIXj[YQh[XCxcITvd4l{yqB? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5NUK3Okc,OjR7N{WyO|Y9N2F-
JJN3 NI\UNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnkNE4yNTFyMDFOwG0> MmTLO|IhcA>? M1e2SWROW09? MluxbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzN{izO|goRjJ|MUe4N|c5RC:jPh?=
XG-1 NIDEN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jrNlAvOS1zMECg{txO M{[2b|czKGh? MYHEUXNQ NW\LTXlbcW6qaXLpeJMh[2WubDDndo94fGh? MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzN{izO|goRjJ|MUe4N|c5RC:jPh?=
CD138+  NIHP[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5NXVGOC5zLUGwNEDPxE1? NVG3bo9nPzJiaB?= Mof3SG1UVw>? MkPRbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NGrhNpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
XG-1 MULGeY5kfGmxbjDBd5NigQ>? MVOyM|ExOCEQvF2= MYWyOEBp M{XDN2ROW09? MXnpcohq[mm2czDDR2w{N02LUD2x{tEhdVKQQTDlfJBz\XO|aX;u M2jYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
U266 M1HOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rEdVAvODFvMUCg{txO M3PCdFQ56oDLaB?= NHvsWpJFVVOR MU\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXzoSYpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVIxODhpPkKyOVUzODB6PD;hQi=>
CRBN60 M4LaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMlAyNTFyIN88US=> MVi0PQKBkWh? NFH5N2lFVVOR MVrpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUKwNFgoRjJ{NUWyNFA5RC:jPh?=
CRNB75 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSwNE4xOS1zMDFOwG0> MYS0PQKBkWh? M4TrTGROW09? NVHmVYdtcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
MM.1S NVnnOGljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjuSlFyOC5yMT2xNEDPxE1? MVG0PQKBkWh? NYnKcY5WTE2VTx?= M2nUNJNq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=> NGiyR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
OPM2 NI\5cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\rRmxpOC5yMT2xNEDPxE1? M{[3dVQ56oDLaB?= Mk\wSG1UVw>? NYHJ[Yd5e2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txO M1vmZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
MM.1S MULGeY5kfGmxbjDBd5NigQ>? M4n2WFExKM7:TR?= MYi3NkBp MXTEUXNQ M2\E[pNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> NFTUb4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
H929 NUXIRm42TnWwY4Tpc44hSXO|YYm= MXGxNEDPxE1? M4fwPFczKGh? M4P6bWROW09? NVPv[Wd4e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXygc4YhSy:HQmFOtkBqe2:ob4Ltd:Kh NWK3Zm5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPFk{OjdpPkKxN|g6OzJ5PD;hQi=>
OPM2 NHviVo1HfW6ldHnvckBCe3OjeR?= MUKxNEDPxE1? NInWO5E4OiCq NUW4cFc3TE2VTx?= Mlz6d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJJBzd3SnaX6gcIV3\Wxib3[gR{9GSlEQsjDpd49nd3Kvc9Mg M4\lPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
CT26 NFrN[FdHfW6ldHnvckBCe3OjeR?= NUTqfFBZOS9zMDFOwG0> MlTINlQhcA>? NGix[nBz\WS3Y3XzJJRp\SCwdX3i[ZJ{KG:oIHzpeoUh[2:ub37p[ZPDqA>? M3XVV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO4PVc4Lz5zOU[zPFk4PzxxYU6=
T-cells NXjqXnNpTnWwY4Tpc44h[XO|YYm= M1;HclIhfG9iMzDkZZl{ MWHJcohq[mm2aX;uJI9nKEmOLUKgdJJw\HWldHnvckBqdiCqdX3hckBVKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEKgeI8hOyCmYYnzJIJ6KEWOSWPBMEBGSzVyIE2gNE4xODhizszNMi=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OECxPUc,OjNzNkiwNVk9N2F-
DF15 M{HXU2Z2dmO2aX;uJIF{e2G7 NVHRPZZyPCCqcoO= MWnJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIFqd2yxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlAzOiEQvF2u M3TPTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
DF15 NInxb45HfW6ldHnvckBie3OjeR?= MkDQOEBpenN? Mn:yTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHX4dJJme3Orbneg[XBNNXSjZ3fl[EBqc2G{b4OgZYZ1\XJiNDDodpMh[nlibIXtbY5wdWW2cnnjJIFv[Wy7c3nzMEBGSzVyIE2gNE4xOjRizszNMi=> M3[4d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
DF15 M2HwTGZ2dmO2aX;uJIF{e2G7 M4DG[|QhcHK| MmLCTY5lfWO2aX;uJI9nKEOUTESvR3JDViC3YnnxeYl1cW5ibHnnZZNmNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHX4dJJme3OrbnegdGxQSy2nUFyteIFo\2WmIHHpc4xweyCjZoTldkA1KGi{czDifUBtfW2rbnXzZ4Vv[2ViYnHz[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKGWweont[UBnemGpbXXueIF1cW:wIHPvcZBt\W2nboTheIlwdiCjc4PhfUwhTUN3MDC9JFAvODJ5IN88UU4> NE\sTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1PFUxPyd-MkizOVg2ODd:L3G+
NAMALWA MkH0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWK3NkBpenN? M1nMS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlHNRWxYSSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEOg{txONg>? MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkiwNVkoRjJ|MU[4NFE6RC:jPh?=
HeLa MkPVSpVv[3Srb36gZZN{[Xl? Ml21TY5pcWKrdHnvckBw\iCLTD2xMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDicI9kc2mwZzDv[kBxPTBxcE[1JI52[2ynYYKgeJJidnOub3PheIlwdixiSVO1NEA:KDFwMkeg{txONg>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzh2NUi1NEc,OTd6NEW4OVA9N2F-
DF15 MmD0SpVv[3Srb36gZZN{[Xl? MmX3NE4xOSC2bzCxJJVO NX;hcpBUPSCqcoO= MoLpTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ NVLQcJVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 M3T2VGZ2dmO2aX;uJIF{e2G7 NF:3O5IxNjBzIITvJFEhfU1? MkjkOUBpenN? Ml7GTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ M2nYRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
DF15 NYHRfIV1TnWwY4Tpc44h[XO|YYm= NYXZWGZ1OC5yMTD0c{AyKHWP NY\F[2I5PSCqcoO= MWLJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> M{P4e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
OPM2 M3jmSGZ2dmO2aX;uJIF{e2G7 M17DblAvODFidH:gNUB2VQ>? NGTN[|E2KGi{cx?= MX3JcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> M{j0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
体内試験

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
細胞試験:

[4]

- 合併
  • 細胞株: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • 濃度: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • 反応時間: 24 or 48 hours
  • 実験の流れ:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.


    (参考用のみ)
動物試験:

[4]

- 合併
  • 動物モデル: Disseminated lymphoma-bearing SCID mice
  • 投薬量: 0.5 mg/kg
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 273.24
化学式

C13H11N3O4

CAS No. 19171-19-8
Storage powder
in solvent
別名 N/A
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03113942 Active not recruiting Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] High Grade Squamous Intra-epithelial Lesion (HSIL) Kirby Institute June 14 2017 Phase 2
NCT02045017 Active not recruiting Drug: Pomalidomide and Dexamethasone Multiple Myeloma Celgene February 28 2014 Phase 2
NCT01177735 Completed Drug: Pomalidomide Multiple Myeloma University of Arkansas|Celgene October 2011 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 質問2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

E3 ligase Ligand Inhibitors with Unique Features

Tags: Pomalidomide (CC-4047)を買う | Pomalidomide (CC-4047) ic50 | Pomalidomide (CC-4047)供給者 | Pomalidomide (CC-4047)を購入する | Pomalidomide (CC-4047)費用 | Pomalidomide (CC-4047)生産者 | オーダーPomalidomide (CC-4047) | Pomalidomide (CC-4047)化学構造 | Pomalidomide (CC-4047)分子量 | Pomalidomide (CC-4047)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID